Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KRRO
stocks logo

KRRO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
420.00K
-81.51%
-2.097
-7.21%
476.67K
-81.31%
-1.994
-19.91%
--
--
-1.856
-32.27%
Estimates Revision
The market is revising Upward the revenue expectations for Korro Bio, Inc. (KRRO) for FY2025, with the revenue forecasts being adjusted by 10.43% over the past three months. During the same period, the stock price has changed by -79.48%.
Revenue Estimates for FY2025
Revise Upward
up Image
+10.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.48%
In Past 3 Month
Stock Price
Go Down
down Image
-79.48%
In Past 3 Month
Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 56.60 USD with a low forecast of 7.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 56.60 USD with a low forecast of 7.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
8 Hold
0 Sell
Hold
Current: 6.810
sliders
Low
7.00
Averages
56.60
High
180.00
Current: 6.810
sliders
Low
7.00
Averages
56.60
High
180.00
Piper Sandler
Yasmeen Rahimi
Overweight -> Neutral
downgrade
$180 -> $11
2025-11-13
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$180 -> $11
2025-11-13
downgrade
Overweight -> Neutral
Reason
Piper Sandler analyst Yasmeen Rahimi downgraded Korro Bio to Neutral from Overweight with a price target of $11, down from $180.
Oppenheimer
Outperform -> Perform
downgrade
2025-11-13
Reason
Oppenheimer
Price Target
2025-11-13
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded Korro Bio to Perform from Outperform.
JonesResearch
Buy
to
Hold
downgrade
2025-11-13
Reason
JonesResearch
Price Target
2025-11-13
downgrade
Buy
to
Hold
Reason
JonesResearch downgraded Korro Bio to Hold from Buy.
JonesResearch
Buy
to
Hold
downgrade
2025-11-13
Reason
JonesResearch
Price Target
2025-11-13
downgrade
Buy
to
Hold
Reason
JonesResearch downgraded Korro Bio to Hold from Buy without a price target after the company announced KRRO-110 did not reach target levels of functional alpha-1 antitrypsin. The firm cites the stock's lack of near-term catalysts and failure to demonstrate proof-of-concept for its RNA editing platform for the downgrade.
Chardan
Keay Nakae
Buy -> Neutral
downgrade
$7
2025-11-13
Reason
Chardan
Keay Nakae
Price Target
$7
2025-11-13
downgrade
Buy -> Neutral
Reason
Chardan analyst Keay Nakae downgraded Korro Bio to Neutral from Buy with a $7 price target. The firm views the negative Phase I/IIa REWRITE trial evaluating KRRO-110 as a "significant setback" for the company. It will require new human clinical data, which now is in 2027, to rebuild investor confidence in Korro's OPERA design platform, the analyst tells investors in a research note.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
$NULL
2025-11-13
Reason
Cantor Fitzgerald
Price Target
$NULL
2025-11-13
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald last night downgraded Korro Bio to Neutral from Overweight without a price target after the company's lead asset KRRO-110 failed. Cantor now sees a "long journey ahead" for Korro.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Korro Bio Inc (KRRO.O) is -0.87, compared to its 5-year average forward P/E of -3.86. For a more detailed relative valuation and DCF analysis to assess Korro Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.86
Current PE
-0.87
Overvalued PE
-2.04
Undervalued PE
-5.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
73.32
Current PS
0.00
Overvalued PS
231.91
Undervalued PS
-85.28
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1445.31% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

KRRO News & Events

Events Timeline

(ET)
2025-11-13
08:34:20
Korro's setback boosts Wave Life Sciences' standing, according to Jefferies.
select
2025-11-12 (ET)
2025-11-12
16:37:10
Korro Bio announces Q3 EPS of $1.92, falling short of consensus estimate of $2.68
select
2025-11-12
16:35:00
Kemi Olugemo Steps Down as Chief Medical Officer of Korro Bio
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-14MarketWatch
Dow's Significant Decline Following Record High is Uncommon: Concerns Over December Rate Cut Impacting Wall Street.

  • Market Performance: Major U.S. equity indexes experienced significant declines, marking their worst percentage-point drops since October 10.

  • Affected Indexes: The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all reported substantial losses on the same day.

[object Object]
Preview
6.0
11-14Benzinga
William Blair Lowers Korro Bio Rating to Market Perform

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
9.0
11-14Benzinga
Korro Bio's Initial Trial Results Disappoint; Shares Reach Record Low

  • Stock Performance: Korro Bio, Inc. (NASDAQ: KRRO) experienced a significant decline in stock price, dropping 80% to $6.27, with a trading volume of 6.68 million shares compared to the average of 1.42 million.

  • Clinical Trial Update: The company reported that its KRRO-110 treatment for alpha-1 antitrypsin deficiency (AATD) produced functional M-AAT protein in patients, but did not meet the expected protein levels based on preclinical data.

  • Strategic Restructuring: Korro is implementing a workforce reduction of approximately 34% to focus on advancing its GalNAc-conjugated programs and extending its cash runway into the second half of 2027.

  • Analyst Downgrade: William Blair downgraded Korro's stock from Outperform to Market Perform, citing concerns over the competitiveness of KRRO-110 and the pause in collaboration with Novo Nordisk.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Korro Bio Inc (KRRO) stock price today?

The current price of KRRO is 6.81 USD — it has increased 12.75 % in the last trading day.

arrow icon

What is Korro Bio Inc (KRRO)'s business?

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

arrow icon

What is the price predicton of KRRO Stock?

Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 56.60 USD with a low forecast of 7.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Korro Bio Inc (KRRO)'s revenue for the last quarter?

Korro Bio Inc revenue for the last quarter amounts to 1.09M USD, decreased % YoY.

arrow icon

What is Korro Bio Inc (KRRO)'s earnings per share (EPS) for the last quarter?

Korro Bio Inc. EPS for the last quarter amounts to -1.92 USD, decreased -15.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for Korro Bio Inc (KRRO)'s fundamentals?

The market is revising Upward the revenue expectations for Korro Bio, Inc. (KRRO) for FY2025, with the revenue forecasts being adjusted by 10.43% over the past three months. During the same period, the stock price has changed by -79.48%.
arrow icon

How many employees does Korro Bio Inc (KRRO). have?

Korro Bio Inc (KRRO) has 104 emplpoyees as of December 05 2025.

arrow icon

What is Korro Bio Inc (KRRO) market cap?

Today KRRO has the market capitalization of 64.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free